Drugs / NKR-2 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03310008 | Aug 2017 → May 2021 | metastasis from malignant tumor of colon | Celyad Oncology SA | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKR-2 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03310008 ↗ |
| Modality | Cell therapy | “multiple administrations of autologous NKR-2 cells” NCT03310008 ↗ |
| Route | Other | “an infusion of NKR-2 cells” NCT03310008 ↗ |